



**ONCONOVA**  
THERAPEUTICS

## **Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference**

September 22, 2022

NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY.

Steven Fruchtman, M.D., President & CEO of Onconova, will present a corporate overview to include an update on the company's portfolio, followed by a 10-minute analyst-led fireside chat, on September 29<sup>th</sup>, 2022, at 12:00 p.m. ET. The presentation can be viewed [here](#) or on the "[Corporate Events and Presentations](#)" section of the Onconova website and will be archived for 90 days. Dr. Fruchtman and other members of the Onconova management team will also be available for in-person one-on-one meetings during the conference on September 29<sup>th</sup>, 2022. Those interested in requesting a meeting should contact their Ladenburg Thalmann representative.

### ***About Onconova Therapeutics, Inc.***

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova's novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova's product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit [www.onconova.com](http://www.onconova.com).

### **Company Contact:**

Mark Guerin  
Onconova Therapeutics, Inc.  
267-759-3680  
[ir@onconova.us](mailto:ir@onconova.us)  
<https://www.onconova.com/contact/>

### **Investor Contact:**

Bruce Mackle  
LifeSci Advisors, LLC  
646-889-1200  
[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)